ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins.


The ImmuNext team combines expert immunology, preclinical development and business development in a tight-knit, well-coordinated team.

Corporate Site

ImmuNext is embedded within the Dartmouth-Hitchcock Medical Center in Lebanon, NH, which affords excellent access to both upstream academic research and downstream translational medicine.


Lebanon, NH provides us with a great combination of intellectual stimulation from Dartmouth College and the beauty of rural New England.